Healthcare Providers and Services
Company Overview of Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center, a cancer hospital, provides cancer treatment services. It offers adult and pediatric cancer care services; specialized treatments and services, including adult blood and marrow stem cell transplantation, pediatric blood and marrow transplantation, and pathology consulting; and symptom management services, such as integrative medicine, palliative care and pain management, rehabilitation, dermatologic health, and cognitive testing. The company also provides services in the areas of counseling, dermatology, fertility, genetic testing and counseling, integrative medicine, nutrition, rehabilitation, resources for life after cancer program, sexual health, an...
1275 York Avenue
New York, NY 10065
Founded in 1884
Key Executives for Memorial Sloan-Kettering Cancer Center
Chief Executive Officer and President
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2013.
Memorial Sloan-Kettering Cancer Center Key Developments
Memorial Sloan Kettering and Eureka Therapeutics Signs Licensing Agreement with Novartis
Jan 29 14
Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. announced that it have entered into a licensing agreement with Novartis AG for the development and commercialization of ESK1, a preclinical stage monoclonal antibody for the treatment of leukemia and other cancers. Memorial Sloan Kettering is a cancer hospital that provides cancer care services, while Eureka Therapeutics is a biotechnology company that focuses on the discovery of human antibody drugs for the treatment of cancer. Both the companies are based in the United States. The ESK1 developed by Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center. Under the terms of the agreement, Eureka Therapeutics and Memorial Sloan-Kettering will receive an up front payment and potential future payments upon achievement of development, regulatory and sales milestones, and
annual net sales royalty payments. Novartis will fund and execute all additional development and commercialization activities.
Memorial Sloan Kettering Cancer Center Presents at Life Sciences Summit 2013, Nov-20-2013 01:15 PM
Oct 3 13
Memorial Sloan Kettering Cancer Center Presents at Life Sciences Summit 2013, Nov-20-2013 01:15 PM. Venue: Convene - Midtown East, 730 Third Avenue (Between East 45th and 46th Streets), 17th Floor, New York, NY 10017, United States. Speakers: Clifford A Hudis, Chief, Breast Cancer Medicine Service.
Foundation Medicine, Inc. and Memorial Sloan-Kettering Cancer Center Announces Partnership to Advance Patient Care in Hematologic Cancers
May 2 13
Foundation Medicine, Inc. and Memorial Sloan-Kettering Cancer Center on May 02, 2013 announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers. This effort will focus on co-development of a new Foundation Medicine molecular diagnostic product designed to match patients with hematologic cancers (leukemia, lymphoma or myeloma) with the most rational targeted therapies or clinical trials for their cancer. Leaders in hematology from Memorial Sloan-Kettering will help accelerate product development by providing clinical and genomic expertise. This product complements FoundationOne(TM), Foundation Medicine's first product, which offers a similar fully informative genomic profile for solid tumors and likewise provides a concise report to assist physicians in matching patients with the targeted drugs or clinical trials best suited for their unique cancer. FoundationOne was launched in 2012. This new test is being developed using RNA sequencing in addition to DNA sequencing to better enable identification of the unique genes and classes of genomic alterations that are characteristic of hematologic malignancies. Similar to FoundationOne, the new hematologic malignancy test will assist physicians by matching these alterations with targeted treatment options that may be relevant to the patient's genomic profile based on a comprehensive review of published literature. The test will be based on technology, methods and computational algorithms developed by Foundation Medicine, and Foundation Medicine will commercialize the test both in the United States and internationally. Memorial Sloan-Kettering will help accelerate the development and optimization of the product by contributing their clinical and genomic expertise in hematologic malignancies. Foundation Medicine operates a CLIA-certified lab in Cambridge, Mass. and receives clinical patient samples from academic medical centers and community hospitals all over the world. The new test is expected to be commercially available by year-end 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|